Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...
Triple-negative breast cancer (TNBC) was first described as a distinct disease entity 20 years ago. Since that time, there has been tremendous effort invested in understanding the clinical features ...
At Thomas’s first oncology appointment, her doctor told her to prepare for the worst. “[It] was absolutely soul crushing,” says Thomas. She immediately searched for other women with triple-negative ...
Systemic therapy de-escalation in early TNBC marks a shift in oncologic management, emphasizing the reduction of treatment intensity without compromising therapeutic efficacy. While the KEYNOTE-522 ...
A new study has identified a set of plasma proteins that can predict whether patients with triple-negative breast cancer (TNBC) will respond to immunotherapy. By analyzing blood samples from 195 TNBC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback